There are currently 441 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
NCT06169371
Recruiting
This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: University of Illinois, Chicago, Illinois +1 locations
Conditions: Breast Cancer
Register for Updates
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945
Recruiting
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Mount Sinai Medical Center, Miami Beach, Florida +69 locations
Conditions: Breast Cancer
Register for Updates
MRg-NIRS Imaging System Breast Cancer Trial
NCT06400563
Recruiting
This trial is a study of 20 women with breast cancer to evaluate the addition of MR-guided (MRg) near-infrared spectroscopy (NIRS) with and without contrast, as part of a program to improve clinical management of women receiving breast magnetic resonance imaging (MRI).
Gender:
FEMALE
Ages:
Between 18 years and 83 years
Trial Updated:
03/24/2025
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Breast Cancer
Register for Updates
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
NCT06902311
Recruiting
This study evaluates the rates of radiation-specific toxicity, quality of life, and oncologic outcomes for early-stage breast cancer and ductal carcinoma in situ treated with 5-fraction whole breast irradiation (WBI) with a simultaneous integrated tumor bed boost (SIB). SIB refers to the technique tumor bed boost given at the same time as standard radiation therapy. The FAST-Forward trial previously showed that a 1-week course of radiotherapy had similar effects to the traditional 3-week course... Read More
Gender:
FEMALE
Ages:
50 years and above
Trial Updated:
03/24/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Breast Cancer, Early-stage Breast Cancer, Ductal Carcinoma in Situ, DCIS
Register for Updates
Collection of Blood From Patients With Cancer
NCT00034216
Recruiting
This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer
Register for Updates
Cryoablation vs Lumpectomy in T1 Breast Cancers
NCT05505643
Recruiting
This trial studies the efficacy and safety of cryoablation in patients with low risk, early stage breast cancer. Cryoablation is a method of killing a tumor by freezing it. The standard approach for patients with this kind of cancer is a lumpectomy. This study will review the safety of the cryoablation procedure initially, followed by comparing cryoablation to lumpectomy in order to see if the cryoablation results in better disease control, complication rates, and quality of life.
Gender:
FEMALE
Ages:
50 years and above
Trial Updated:
03/21/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Breast Cancer, Breast Neoplasm
Register for Updates
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
NCT05190978
Recruiting
Surgical mesh products, particularly acellular dermal matrices (ADM), are now used by the majority of plastic surgeons to assist with the nearly 100,000 prosthetic breast reconstruction procedures in the United States, despite never being approved by Food and Drug Administration (FDA) for this indication. As surgeons transition to placing breast implants above the chest muscle (pre-pectoral), there has been an increasing reliance on these often expensive mesh products without robust evidence to... Read More
Gender:
FEMALE
Ages:
Between 22 years and 75 years
Trial Updated:
03/20/2025
Locations: University of California Los Angeles, Los Angeles, California
Conditions: Breast Cancer, Breast Implant; Complications, Infection or Inflammation
Register for Updates
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
NCT05675579
Recruiting
To learn if sacituzumab govitecan and pembrolizumab, when given before surgery, can help to control early-stage triple negative breast cancer that has not responded well to other treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
NCT03572374
Recruiting
The purpose of this study is learn more about how being treated for breast cancer affects patients' employment. Researchers are testing an early version of a mobile app designed to help breast cancer patients keep their jobs during and after treatment. The app provides advice for patients to use when having conversations about breast cancer with their employers and their doctors. The app is called TEAMWork (Talking to Employers And Medical staff about Work). In this study, the investigators are... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Memorial Sloan Kettering Basking Ridge (Consent and Follow-up), Basking Ridge, New Jersey +8 locations
Conditions: Breast Cancer
Register for Updates
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT04768426
Recruiting
The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from treatment with capecitabine. Participants will be monitored for changes in ctDNA in the blood over time received during capecitabine treatment. Results of ctDNA analysis will be correlated to genetic characteristics of individual tumors. This may inform future clinical tria... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Stanford University, Stanford, California
Conditions: Triple Negative Breast Cancer, Breast Cancer
Register for Updates
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845
Recruiting
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona +13 locations
Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
Register for Updates
[18F] F-GLN by PET/CT in Breast Cancer
NCT03863457
Recruiting
Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC). This... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Breast Cancer
Register for Updates